Reboxetine Versus Fluvoxamine in the Treatment of Motor Vehicle Accident-related Posttraumatic Stress Disorder: A Double-blind, Fixed-dosage, Controlled Trial
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Motor vehicle accidents (MVAs) are a leading cause of posttraumatic stress disorder (PTSD) in the general population. Alterations in norepinephrine and serotonin systems have been proposed as mechanisms involved in the pathophysiology of the condition, with treatment directed at these neurotransmitter systems. Reboxetine, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the human norepinephrine transporter. Inasmuch as PTSD may be associated with dysregulation of noradrenergic activity, the present double-blind randomized clinical trial intended to evaluate reboxetine's efficacy in the management of MVA-related PTSD and to compare its efficacy with a medication commonly used in PTSD, the selective serotonin reuptake inhibitor fluvoxamine. METHODS: Forty patients with MVA-related PTSD attending a local community mental health outpatient clinic were randomized to receive a fixed dose of either reboxetine (8 mg/d) or fluvoxamine (150 mg/d) in a double-blind fashion for a period of 8 weeks. RESULTS: At baseline and at study end point, the 2 subgroups demonstrated no statistical differences in scores on PTSD, depression, and anxiety rating scales. Both medications led to significant improvements in all clinical scales measured. Nine patients receiving reboxetine and 3 receiving fluvoxamine withdrew from the study because of side effects. CONCLUSIONS: Study observations indicate comparable efficacy of reboxetine and fluvoxamine in the management of MVA-related PTSD despite reboxetine's selective noradrenergic activity. Reboxetine appears to be at least as effective as fluvoxamine and may offer an alternative management option in this often difficult-to-treat and disabling condition. A lower and flexible reboxetine dosing schedule will be recommended for future research to improve its tolerability in PTSD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Psychiatric consequences of road traffic accidents
Mayou, R., Bryant, B., & Duthie, R. (1993) · BMJ · doi:10.1136/bmj.307.6905.647 · Cited by 626 · cited 1×
“In addition to significant mortality and medical morbidity rates, MVAs can also lead to a wide range of acute and chronic psychological consequences,(4) with MVA-related posttraumatic stress disorder (MVARPTSD) being the most common.(5) Most notably, MVAs have been found to be the leading cause of PTSD in the general…”
BackgroundRole of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder
Southwick, S. M., Bremner, J. D., Rasmusson, A., Morgan, C. A., Arnsten, A., & Charney, D. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00219-x · Cited by 573
CSF Norepinephrine Concentrations in Posttraumatic Stress Disorder
Geracioti, T. D., Baker, D. G., Ekhator, N. N., West, S. A., Hill, K. K., Bruce, A. B., Schmidt, D., Rounds-Kugler, B., Yehuda, R., Keck, P. E., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1227 · Cited by 462
Birnbaum, S., Gobeske, K. T., Auerbach, J., Taylor, J. R., & Arnsten, A. F. T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00138-9 · Cited by 281
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“small RCT (both Level 2) [984], and open-label studies suggest that bupropion SR [1003], duloxetine [990,991], escitalopram [985], moclobemide [997,998], and tianeptine [997,1004] (all Level 3) may be useful in PTSD.”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…sertraline was not [I (PCT)] (Davidson et al., 2006b); reboxetine had similar effectiveness but lower overall tolerability than fluvoxamine [II] (Spivak et al., 2006); and mirtazapine had somewhat greater than effectiveness than sertraline, in a randomised but ‘open’ trial [II] (Chung et al.,…”
ResultPharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis
Hoskins, M., Pearce, J., Bethell, A., Dankova, L., Barbui, C., Tol, W. A., van Ommeren, M., de Jong, J., Seedat, S., Chen, H., et al. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148551 · Cited by 418
Pharmacotherapy of PTSD: premises, principles, and priorities.
Ravindran, L. N., & Stein, M. B. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.037 · Cited by 153
Metadata
- Authors
- Spivak, B., Strous, R. D., Shaked, G., Shabash, E., Kotler, M., & Weizman, A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2006-04
- Volume
- 26
- Issue
- 2
- Pages
- 152-156
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2041922705
- Cited by
- 33
- References
- 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reboxetine Versus Fluvoxamine in the Treatment of Motor Vehicle Accident-related Posttraumatic Stress Disorder: A Double-blind, Fixed-dosage, Controlled Trial. https://app.cochat.ai/papers/10.1097/01.jcp.0000203195.65710.f0
- The paper
- Spivak, B., Strous, R. D., Shaked, G., Shabash, E., Kotler, M., & Weizman, A. (2006). Reboxetine Versus Fluvoxamine in the Treatment of Motor Vehicle Accident-related Posttraumatic Stress Disorder: A Double-blind, Fixed-dosage, Controlled Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000203195.65710.f0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.